Drug
Melt 300 Sublingual
Melt 300 Sublingual: highest development phase Phase 3, developed by United Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| MELT-300 sublingual tablet NCT06383273 | Phase 3 | Cataract |
Latest
No recent events.
Follow Melt 300 Sublingual on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.